Find Funding Opportunities

The purpose of this notice is to direct visitors who land on the terminated FOA PAR-19-164 to the current FOA PAR-21-168.

The purpose of this notice is to inform applicants of a correction to PAR-21-237 "NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)".

The purpose of this notice is to inform applicants of NINDS' participation in RFA-MD-22-004 "Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)" effective immediately.

The purpose of this time-sensitive Request for Information (RFI) is to solicit public input to the NINDS regarding the challenges and opportunities in fundamental neuroscience research to best understand the normal development, structure, and function of nervous systems.

The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials.The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications to identify biomarkers or biomarker signatures that predict or monitor a therapeutic response across several related pain conditions should feature Multiple Principal Investigator (MPI)-led teams that represent each of the related pain conditions and associated clinical networks. The MPI-led teams are expected to decide upon a single set of measures or biomarker modalities (i.e., combination of omics, QST, actigraphy, EEG, digital measures, etc.) as components of the biosignature for all pain conditions represented in the application. Applications should feature centralized resource groups that will coordinate clinical trials and standardize all sample or data collection methods, technology development, statistical analysis and algorithm development across the pain conditions under investigation. Applications seeking to develop biomarkers or biomarker signatures that will be used to predict and/or monitor a therapeutic response for a single pain condition must also feature MPI-led teams that represent the cross functional expertise necessary for biomarker and/or signature development, along with the same types of centralized resource groups that coordinate clinical trials and standardize sample or data collection methods, technology development and statistical analysis.

The purpose of this time-sensitive Request for Information (RFI) is to solicit public input to the NINDS regarding the challenges and opportunities in fundamental neuroscience research to best understand the normal development, structure, and function of nervous systems.

RE-JOIN Technical Assistance Webinar

The purpose of this notice is to correct the Award Project Period Information for Funding Opportunity Announcement (FOA) PAS-19-316 "Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional). According to statutory guidelines, award periods normally may not exceed 2 years for Phase I and 3 years for Phase II. As such, NIA has changed the award period for Phase I from 1 year to 2 years and the award period for Phase II from 2 years to 3 years.

The purpose of this notice is to correct the Award Project Period Information for Funding Opportunity Announcement (FOA) PAS-19-317, "Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional). Specifically, according to statutory guidelines, award periods normally may not exceed 2 years for Phase I and 3 years for Phase II. As such, NIA has changed the award period for Phase I from 1 year to 2 years and the award period for Phase II from 2 years to 3 years.

This notice describes opportunities available to CRCNS grantees to support the use of such resources. The Cloud Access Program (NSF) and the STRIDES Initiative (NIH) have established partnerships with commercial cloud service providers to provide awardees with cost-effective, flexible access to cloud-based resources. The Partnership to Advance Throughput Computing (PATh) facilitates access to distributed high throughput computing technologies and services. These opportunities are now available to active CRCNS grantees as described below.